Biogen Inc. (BIIB)
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.
Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about its treatment for kidney-transplant rejections.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
Biogen Inc.'s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial
Biogen-UCB's lupus drug meets main goal of late-stage trial
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Cantor Fitzgerald Global Healthcare Conference Call September 18, 2024 1:20 PM ET Company Participants Chuck Triano - Head, Investor Relations Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. If you could take a seat?
